ONCAlert | 2017 San Antonio Breast Cancer Symposium

Lenvatinib in Thyroid Cancer With and Without VEGF-Targeted Therapy

Matthew H. Taylor, MD
Published Online: 8:03 PM, Mon June 1, 2015


Matthew H. Taylor, MD, Oregon Health and Science University, discusses the efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.